Pharmaceutical Technology
APRIL 14, 2023
Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Foralumab is a fully human anti-CD3 monoclonal antibody, which works by binding to the T-cell receptor and regulating T-cell function to reduce pulmonary inflammation.
Pharma Mirror
SEPTEMBER 6, 2023
Compliance with complex laws and regulations, like Direct-to-Consumer Advertising (DTCA) Rules or the Health Insurance Portability and Accountability Act (HIPAA), can be quite daunting. And it is not hard to see why.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cloudbyz
MAY 17, 2024
This Act is poised to significantly change the clinical trials landscape within the life sciences sector. As AI increasingly becomes a cornerstone in clinical research and drug development, it is crucial for industry stakeholders to grasp the extensive implications of this regulation.
Pharmaceutical Technology
JULY 28, 2022
In the life sciences sector, one country is significantly outstripping others for FDI. Data shows that almost 40% of all life sciences subsidiaries are located in the US. After all, around a third of the world’s leading life sciences corporations have their headquarters in the country.
Cloudbyz
NOVEMBER 22, 2024
We are deeply honored to be recognized in Everest Group’s PEAK Matrix® for Life Sciences CTMS solutions,” said Dinesh Kashyap, CEO and Founder of Cloudbyz. Our mission is to enable faster, more efficient trials, ultimately supporting the delivery of life-saving therapies.”
FDA Law Blog
JULY 30, 2024
By Sara M Keup & Véronique Li, Senior Medical Device Regulation Expert — The American Conference Institute (“ACI”) held its 11th Annual Summit for Women Leaders in Life Sciences Law at the Seaport Hotel in Boston, Massachusetts on July 25th & 26th of last week. Advertising Challenges in Life Sciences.
Cloudbyz
SEPTEMBER 10, 2023
The challenge of managing and securing sensitive data, including PHI and PII, is significant for life sciences organizations. At the same time, the regulatory environment is becoming increasingly complex, with new data protection regulations being introduced regularly.
Expert insights. Personalized for you.
246 
Let's personalize your content